

## HR 8877

Biologics Competition Act of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Sep 19, 2022

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Sep 20, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/8877>

### Sponsor

**Name:** Rep. Miller-Meeks, Mariannette [R-IA-2]

**Party:** Republican • **State:** IA • **Chamber:** House

### Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Barragan, Nanette Diaz [D-CA-44]	D · CA		Sep 19, 2022
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Sep 19, 2022
Rep. Murphy, Gregory [R-NC-3]	R · NC		Sep 19, 2022
Rep. Bice, Stephanie I. [R-OK-5]	R · OK		Sep 29, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Sep 20, 2022

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

*No related bills are listed.*

## **Biologics Competition Act of 2022**

This bill requires the Food and Drug Administration (FDA) to evaluate (1) the differences between the requirements that apply to interchangeable biologics and the requirements that apply to therapeutically equivalent ratings for generic drugs, and (2) the effects of these differences on the approval of interchangeable biologics. The FDA must update the Purple Book with changes that better align the ways these requirements are communicated while still maintaining each distinct approval pathway.

The Purple Book is an FDA publication that lists approved biological products, including biosimilars and interchangeable biologics. Interchangeable biologics are biologics that may be substituted for the original product without consulting the prescriber, similar to how generic drugs may be substituted for brand-name drugs based on therapeutic equivalence.

## **Actions Timeline**

---

- **Sep 20, 2022:** Referred to the Subcommittee on Health.
- **Sep 19, 2022:** Introduced in House
- **Sep 19, 2022:** Referred to the House Committee on Energy and Commerce.